Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2945627 | 0.76 | NPC1 (0.41) | L3MBTL1ALDH1A1MAPTHRH3MEN1 | |
| SCHEMBL16739572 | 0.74 | ALDH1A1 (0.49) | L3MBTL1HTTATMALDH1A1MAPT | |
| Ethyl 3-Phenylpropanoate SCHEMBL304816 | 0.74 | TDP1 (0.75) | CYP4F2CYP4A11TDP1ABCB1L3MBTL1 | |
| Ethyl 3-Phenylpropanoate SCHEMBL7440447 | 0.73 | TDP1 (0.72) | CYP4F2CYP4A11TDP1ABCB1L3MBTL1 | |
| SCHEMBL4425984 | 0.73 | CYP4F2 (0.64) | CYP4F2CYP4A11TDP1ABCB1ALDH1A1 | |
| SCHEMBL19220399 | 0.73 | KDM4E (0.55) | CYP4F2CYP4A11LMNATDP1L3MBTL1 | |
| SCHEMBL9858129 | 0.72 | TDP1 (0.66) | CYP4F2CYP4A11TDP1ABCB1L3MBTL1 | |
| SCHEMBL68902 | 0.72 | CYP4F2 (0.85) | CYP4F2CYP4A11LMNATDP1ABCB1 | |
| Ethyl 3-Phenylpropanoate SCHEMBL311047 | 0.70 | TDP1 (0.68) | CYP4F2CYP4A11TDP1ABCB1L3MBTL1 | |
| Ethyl 3-Phenylpropanoate SCHEMBL3322728 | 0.70 | CYP4F2 (0.70) | CYP4F2CYP4A11TDP1ABCB1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004233-A1 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004233-A1 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004233-A1 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2010085820-A2 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010085820-A2 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004233-A1 | TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | CYP4F2 1123/4885CYP4A11 661/4885LMNA 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.